BALTIMORE, MD--(Marketwired - Jun 6, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, reports that a recent study published in in the Journal of Biology Chemistry found that Epigallocatechin gallate (EGCG) has demonstrated the ability to serve as a treatment for Alzheimer's disease, which could serve as a major positive for Plandai. EGCG is the most abundant catechin found in green tea and serves as a key component of the Company's flagship offering. Plandai Biotechnology is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
The Alzheimer study, which occurred in the lab, was shown to stop amyloid-beta proteins from attaching to and killing brain cells in a lab setting by changing the shape of the proteins by applying ECGC. These proteins have been identified in many studies and trials as proteins that play a role in the disease. The Alzheimer's Association notes that Alzheimer's disease is the sixth-leading cause of death in the United States and the only cause of death among the top 10 in the U.S. that cannot be prevented, cured or even slowed. As a result, according to the National Institutes of Health, over 1,000 clinical trials are underway to fight this disease, which affects 5 million people in the U.S. and is expected to nearly triple by 2050.
Clearly, additional studies will be undertaken to eventually confirm these early results in a human clinical trial setting. Given that Plandai's Phytofare™ is engineered to produce extremely high bioavailability and pharmaceutical-grade purity, Plandai could emerge as a primary source of ECGC via its Phytofare™ Catechin Complex for these studies. Moreover, these encouraging results could prompt greater consumption of green tea and its antioxidant extracts as an Alzheimer's preventive tool. Therefore, producers touting ECGC's properties in such treatments could select Plandai as a large scale, go-to source of extract in its offerings, serving as a boon to Plandai's business and industry status.
Additional detail via the Goldman Small Cap Research article as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (